Currently Viewing:
Currently Reading
PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care
October 04, 2016 – Surabhi Dangi-Garimella, PhD
Knowledge Is Power for Cancer Patients, British Study Says
October 03, 2016 – Christina Mattina
Remarkable Outcomes With Cancer Immunotherapy, but Clinical Adoption Remains Challenging
October 03, 2016 – Surabhi Dangi-Garimella, PhD
Higher Heart Rate Linked to Increased Mortality, Hospitalization Among African Americans
October 03, 2016 – Mary Caffrey
This Week in Managed Care: October 1, 2016
October 01, 2016
ICER Recommends Significant Discount on WAC for Checkpoint Inhibitors in NSCLC
September 30, 2016 – Surabhi Dangi-Garimella, PhD
New Anticancer Drugs Associated With Big Increases in Costs, but Also Life Expectancy
September 30, 2016 – Jackie Syrop
What We're Reading: Senate Passes Government Budget Bill With Zika Virus Funding
September 29, 2016 – AJMC Staff
Preventive Oophorectomy Contraindicated in Women With an Average Risk of Ovarian Cancer
September 29, 2016 – Surabhi Dangi-Garimella, PhD

PanCAN's Precision Medicine Trial Designed for Collaboration and Personalized Care

Surabhi Dangi-Garimella, PhD
Precision Promise, the Pancreatic Cancer Action Network (PanCAN)'s precision medicine trial, seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020.
With the announcement of Precision Promise, the Pancreatic Cancer Action Network (PanCAN) seeks to transform outcomes for pancreatic cancer patients with the goal set to double survival by 2020. The trial is focused on boosting the dismal clinical trial-enrollment rate and using a personalized approach to care.  

The PanCAN trial will evaluate the molecular nature of the patient’s tumor to mark mutations and direct the patient to the most suitable sub-study arm of the trial—reflecting the principles of the NCI-MATCH (National Cancer Institute Molecular Analysis for Therapy Choice) and TAPUR (Targeted Agent and Profiling Utilization Registry) trials. The PanCAN trial offers patients the flexibility to move between arms based on their response to therapy without having to wait between different clinical trials.

The following 12 sites, selected via a competitive peer-reviewed process, will begin enrolling trial participants in the Clinical Trial Consortium:
  1. Dana Farber/Harvard Cancer Center
  2. Memorial Sloan Kettering Cancer Center
  3. University of Pennsylvania
  4. University of Florida
  5. Washington University
  6. University of Michigan
  7. University of Chicago
  8. Virginia Mason
  9. Fred Hutchison Cancer Research Center/Seattle Cancer Care Alliance/University of Washington
  10. University of California, San Francisco
  11. Cedars-Sinai
  12. University of California, San Diego
The Consortium includes 5 working groups, comprised of leading researchers with expertise in specific aspects of pancreatic cancer:
  • DNA damage repair working group
  • Stromal disruption working group
  • Immunotherapy working group
  • Supportive care working group
  • Industry working group
Under the umbrella of Precision Promise, data collected from all 12 sites will be collated and analyzed together for efficient and timely dissemination of trial data. The trial will initially have a 3-pronged approach toward the disease: DNA damage repair, stromal disruption, and immunotherapy; however, it has been designed to add new arms and sub-studies based on novel research findings.

With an initial commitment of $35 million over the first 4 years—excluding drug costs—the trial expects to enroll thousands of participants starting spring 2017.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up